Bharat Biotech’s Nucelion Partners VeGen Bio to Develop India’s First Dual-Target CAR-T Therapy
The story in brief
Bharat Biotech’s CRDMO arm Nucelion has partnered with VeGen Bio to develop India’s first dual-target CAR-T therapy, VL-2511, for multiple myeloma. The collaboration will advance VL-251, which targets BCMA and CD19, into Phase 1 and 2 trials and eventually commercialise it by 2028. The partnership will focus on manufacturing and scaling up the therapy at Nucelion’s Hyderabad facility.